All eyes are on the biopharmaceutical industry as the world waits for an end to the COVID-19 pandemic, hopefully through a vaccine against the novel coronavirus. Investors are putting their money behind drug developers with any amount of potential to thwart COVID-19 – including Moderna Inc. with its recent $1.34bn stock offering – which is contributing to soaring biopharma values despite the toll that the coronavirus is taking on the global economy.
[Sidebar#SC142246]






